Vasoactive intestinal peptide re-balances TREM-1/TREM-2 ratio in acute lung injury

Regul Pept. 2011 Feb 25;167(1):56-64. doi: 10.1016/j.regpep.2010.11.008. Epub 2010 Dec 2.

Abstract

Vasoactive intestinal peptide (VIP) is one of the most plentiful neuropeptides in the lung and it has anti-inflammatory effects in the respiratory system. Triggering receptors expressed on myeloid cells-1 (TREM-1) and triggering receptors expressed on myeloid cells-2 (TREM-2) regulate immune responses to lipopolysaccharide (LPS). In the present study, we tested the expressions of TREM-1 and TREM-2 in various pulmonary cell lines and/or tissue using an animal model of LPS-induced acute lung injury (ALI), and determined the effects of VIP on expression of the TREM-1 and TREM-2 in lung tissues and cells from ALI mice. We found 1) expression of the TREM-1 mRNA from lung tissues of ALI was significantly increased, whereas the expression of TREM-2 mRNA was decreased in these tissues; 2) TREM-1 mRNA was only expressed in macrophages, while TREM-2 mRNA was detected in HBECs, lung fibroblasts, lung adenocarcinoma cells and macrophages; 3) the ratio of TREM-1 mRNA to TREM-2 mRNA was increased in LPS-induced lung tissues and macrophages; 4) VIP inhibited expression of the TREM-1 mRNA in a time- and dose-dependent manner in lung cells from LPS-induced ALI mice; however, it increased expression of the TREM-2 mRNA. As a result of these effects, VIP normalized the ratio of TREM-1 to TREM-2 mRNA in these cells. Our results suggest that VIP might exert its anti-inflammatory effect through a mechanism involved in regulation of expression of the TREM-1 and TREM-2 in LPS-induced ALI.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / chemically induced
  • Acute Lung Injury / genetics
  • Acute Lung Injury / metabolism*
  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism
  • Adenocarcinoma of Lung
  • Animals
  • Anti-Inflammatory Agents / metabolism
  • Cell Line, Tumor
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Gene Expression Regulation
  • Inflammation / genetics
  • Inflammation / metabolism*
  • Lipopolysaccharides / pharmacology
  • Lung / physiopathology
  • Lung Neoplasms / genetics
  • Lung Neoplasms / metabolism
  • Male
  • Membrane Glycoproteins / genetics
  • Membrane Glycoproteins / metabolism*
  • Mice
  • Myeloid Cells / cytology
  • Myeloid Cells / drug effects
  • Myeloid Cells / metabolism
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Neuroprotective Agents / metabolism*
  • Neuroprotective Agents / pharmacology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / metabolism*
  • Triggering Receptor Expressed on Myeloid Cells-1
  • Vasoactive Intestinal Peptide / genetics
  • Vasoactive Intestinal Peptide / metabolism*
  • Vasoactive Intestinal Peptide / pharmacology

Substances

  • Anti-Inflammatory Agents
  • Lipopolysaccharides
  • Membrane Glycoproteins
  • Neuroprotective Agents
  • RNA, Messenger
  • Receptors, Immunologic
  • TREM1 protein, mouse
  • Trem2 protein, mouse
  • Triggering Receptor Expressed on Myeloid Cells-1
  • Vasoactive Intestinal Peptide